The role of PPARγ-dependent pathway in the development of cardiac hypertrophy

被引:9
|
作者
Takano, H [1 ]
Hasegawa, H [1 ]
Nagai, T [1 ]
Komuro, I [1 ]
机构
[1] Chiba Univ, Dept Cardiovasc Sci & Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan
来源
DRUGS OF TODAY | 2003年 / 39卷 / 05期
关键词
D O I
10.1358/dot.2003.39.5.799458
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily. PPARs have three isoforms, alpha, beta (or delta) and gamma. It has been conceived that PPARgamma is expressed predominantly in adipose tissue and promotes adipocyte differentiation and glucose homeostasis. Recently, synthetic antidiabetic thiazolidinediones and natural prostaglandin D-2 (PGD(2)) metabolite, 1 5-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), have been identified as ligands for PPARgamma. Following demonstration that PPARgamma is present in a variety of cell types, further study of PPARgamma has been conducted. Although activation of PPARgamma appears to have beneficial effects on atherosclerosis and heart failure, it is still largely uncertain whether PPARgamma ligands prevent the development of cardiovascular diseases. Recent evidence suggests that some benefit from the antidiabetic agents known as thiazolidinediones may occur through PPARgamma-independent mechanisms. In this review, we report on the latest developments concerning the study of PPARs and summarize the roles of the PPARgamma-dependent pathway in cardiovascular diseases. (C)2003 Prous Science. All rights reserved.
引用
收藏
页码:347 / 357
页数:11
相关论文
共 50 条
  • [1] A role for PPARα in sex differences in cardiac hypertrophy
    Fillmore, Natasha
    Harrington, Josephine
    Gao, Shouguo
    Yang, Yanqin
    Zhang, Xue
    Liu, Poching
    Stoehr, Andrea
    Springer, Danielle
    Zhu, Jun
    Wang, Xujing
    Murphy, Elizabeth
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 112 : 141 - 142
  • [2] Transcriptomic analysis of PPARα-dependent alterations during cardiac hypertrophy
    Smeets, Pascal J. H.
    de Vogel-van den Bosch, Heleen M.
    Willemsen, Peter H. M.
    Stassen, Alphons P.
    Ayoubi, Torik
    van der Vusse, Ger J.
    van Bilsen, Marc
    PHYSIOLOGICAL GENOMICS, 2008, 36 (01) : 15 - 23
  • [3] The role of cyclin-dependent kinase 6 in cardiac development and hypertrophy
    Bryan, Crystal
    Blanton, Robert
    Aronovitz, Mark
    Karas, Richard
    Hu, Miaofen
    Hinds, Philip W.
    FASEB JOURNAL, 2013, 27
  • [4] A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
    Molkentin, JD
    Lu, JR
    Antos, CL
    Markham, B
    Richardson, J
    Robbins, J
    Grant, SR
    Olson, EN
    CELL, 1998, 93 (02) : 215 - 228
  • [5] Pristimerin protects against pathological cardiac hypertrophy through improvement of PPARα pathway
    Lu, Ye
    Zeng, Zhaoxiang
    Bao, Xianhao
    Wu, Mingwei
    Jing, Zaiping
    Feng, Jiaxuan
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2023, 473
  • [6] The role of Hippo signaling pathway in physiological cardiac hypertrophy
    Gholipour, Majid
    Tabrizi, Arezoo
    BIOIMPACTS, 2020, 10 (04) : 250 - 256
  • [7] ST1929, a PPARα agonist, counteracts cardiac dysfunction development in hamster with cardiac hypertrophy
    Lo Giudice, P
    Sciarroni, AF
    Milazzo, F
    Di Lisa, F
    Dell'Uomo, N
    Giannessi, F
    Carminati, P
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (05) : 743 - 743
  • [8] A crucial role of HB-EGF in the pathway of cardiac hypertrophy
    Asakura, M
    Kitakaze, M
    Takashima, S
    Hori, M
    CIRCULATION, 2000, 102 (18) : 35 - 35
  • [9] Role of the phosphoinositide 3-kinase pathway in cardiac hypertrophy
    Shioi, T
    McMullen, JR
    Izumo, S
    PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE, 2004, 10 : 87 - 100
  • [10] Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway
    Obata, K
    Nagata, K
    Iwase, M
    Odashima, M
    Nagasaka, T
    Izawa, H
    Murohara, T
    Yamada, Y
    Yokota, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 338 (02) : 1299 - 1305